What is Theraclone Sciences?
Theraclone Sciences operates at the intersection of immunology and drug discovery, specializing in the rapid identification of rare human monoclonal antibodies. With over a decade of rigorous scientific development, the company has engineered a comprehensive platform designed to isolate potent antibodies that can effectively combat diseases. This technological edge has enabled the firm to secure high-value licensing agreements, most notably with Gilead for HIV-cure regimens and OncoResponse for oncology-focused applications. By bridging the gap between academic research and clinical-grade therapeutic development, Theraclone provides essential value to the pharmaceutical industry, offering a robust pipeline of candidates that address significant unmet medical needs.
How much funding has Theraclone Sciences raised?
Theraclone Sciences has raised a total of $35.5M across 4 funding rounds:
Series A
$2M
Series B
$29M
Unspecified
$1.5M
Private Equity
$3.1M
Series A (2004): $2M, investors not publicly disclosed
Series B (2007): $29M led by HealthCare Ventures, Canaan Partners, MPM Capital, ARCH Venture Partners, Amgen Business Development, and Alexandria Real Estate Equities
Unspecified (2010): $1.5M supported by Canaan Partners, Healthcare Ventures, MPM Capital, ARCH Venture Partners, Amgen Business Development, and Alexandria Real Estate Equities
Private Equity (2015): $3.1M, investors not publicly disclosed
Key Investors in Theraclone Sciences
Canaan Partners
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health.
HealthCare Ventures
HealthCare Ventures is a leading life science venture capital firm investing in pre-clinical or early clinical stage, focused companies with potential to transform patient care.
MPM Capital
MPM BioImpact manages early-stage venture funds, private/public impact funds and a public equities fund, converting science into therapeutics to reach the patients that need them most.
What's next for Theraclone Sciences?
Looking ahead, Theraclone Sciences is poised to leverage its enterprise-level funding to deepen its clinical footprint. The strategic focus will likely center on expanding its platform utility across diverse therapeutic areas, potentially unlocking new revenue streams through additional licensing deals and collaborative research initiatives. As the company matures, the emphasis will shift toward scaling its internal development capabilities and navigating the regulatory pathways required to bring its innovative antibody candidates to market. With a proven track record of successful partnerships, Theraclone is well-positioned to maintain its competitive advantage in the rapidly evolving landscape of precision medicine and immunotherapy.
See full Theraclone Sciences company page
